Review: Cancer morphogenesis: Role of mitochondrial failure

Annals of Clinical and Laboratory Science

Volumn 38, Issue 4, 2008, Pages 307-330

  Fosslien, Egil ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NONE   (United States)

Author keywords

Cancer; Carcinogen; Dual genome disease; Krebs cycle; Mitochondrial failure; Mitochondrial toxins; Morphogen gradient; Morphogenesis; MtDNA; nDNA; OXPHOS; Teratogen

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; CARCINOGEN; CARRIER PROTEIN; CYCLIC AMP; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME C OXIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MORPHOGEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; PHTHALIC ACID; POLYCYSTIN 1; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTON PUMP; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SCATTER FACTOR; STATIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCOUPLING PROTEIN; UNINDEXED DRUG;

CANCER RISK; CARCINOGENESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CELL TRANSPLANTATION; CHICK EMBRYO; CITRIC ACID CYCLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; ENERGY RESOURCE; GENE MUTATION; GLYCOLYSIS; HORMESIS; INFLAMMATION; MELANOMA CELL; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MORPHOGENESIS; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PLASTIC BOTTLE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TISSUE STRUCTURE; ANIMAL; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ENERGY METABOLISM; HUMANS; MITOCHONDRIAL DISEASES; MORPHOGENESIS; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS;

EID: 55949122944     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (198)

1. Tabata T, Takei Y. Morphogens, their identification and regulation. Development 2004;131:703-712.
2. Barker N, Morin PJ, Clevers H. The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000;77:1-24.
3. Edlund S, Lee SY, Grimsby S, Zhang S, Aspenström P, Heldin CH, Landström M. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005;25:1475-1488.
4. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990;63:515-524.
5. Qiu L. Regulatory role of hormones and growth factors in the pathogenesis of human uterine leiomyomas. Ph.D. Thesis in Pathology. Graduate College of the UIC Health Sciences Center, Chicago, 1995 (Major advisor: E. Fosslien).
6. Fosslien E. Lin Q, Yamashiroya H. Human uterine leiomyoma cells: Growth responses to epidermal growth factor and transforming growth factor beta. Ann Clin Lab Sci 1997;27: 318-319.
7. McAnulty RJ, Hernández-Rodriguez NA, Mutsaers SE, Coker RK, Laurent GJ. Indomethacin suppresses the anti-proliferative effects of transforming growth factor-beta isoforms on fibroblast cell cultures. Biochem J 1997;321:639-643.
8. Calabrese E. Hormesis: why it is important to toxicology and toxicologists. Environ Toxicol Chem 2008:7:1451-1474.
9. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P, Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev 2005;19:1849-1854.
10. Fosslien E. Establishment, maintenance, and remodeling of curvature in biology. Med Hypotheses 2002;59:233-238.
11. Fosslien E. Cardiovascular complications of non-steroidal antiinflammatory drugs. Ann Clin Lab Sci 2005;35:347-385.
12. Montesano R, Carrozzino F, Soulié P. Low concentrations of transforming growth factor-beta-1 induce tubulogenesis in cultured mammary epithelial cells. BMC Dev Biol 2007;7:7
13. Gemin A, Sweet S, Preston TJ, Singh G. Regulation of the cell cycle in response to inhibition of mitochondrial generated energy. Biochem Biophys Res Commun 2005;332:1122-1132.
14. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA; Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-410.
15. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simóes M. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid. Br J Cancer 2005;92: 1892-1898.
16. Jones CM, Armes N, Smith JC. Signalling by TGF-beta family members: short-range effects of Xnr-2 and BMP-4 contrast with the long-range effects of activin. Curr Biol 1996;6:1468-1475.
17. McDowell N, Zorn AM, Crease DJ, Gurdon JB. Activin has direct long-range signalling activity and can form a concentration gradient by diffusion. Curr Biol 1997;7:671-681.
18. Sasaki T, Ito Y, Bringas P Jr, Chou S, Urata MM, Slavkin H, Chai Y. TGF-beta-mediated FGF signaling is crucial for regulating cranial neural crest cell proliferation during frontal bone development. Development 2006;133:371-381.
19. Oklü R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 2000;5;352 Pt 3:601-610.
20. Fantel AG, Person RE. Involvement of mitochondria and other free radical sources in normal and abnormal fetal development. Ann N Y Acad Sci 2002;959:424-433.
21. Rull RP, Ritz B, Shaw GM. Neural tube defects and maternal residential proximity to agricultural pesticide applications. Am J Epidemiol 2006;163:743-753.
22. Shinde SB, Save VC, Patil ND, Mishra KP, Tendolkar AG. Impairment of mitochondrial respiratory chain enzyme activities in tetralogy of Fallot. Clin Chim Acta 2007;377:138-143.
23. Montenegro MA, Palomino H. Induction of cleft palate in mice by inhibitors of prostaglandin synthesis. J Craniofac Genet Dev Biol 1990;10:83-94.
24. Child CM. A dynamic conception of the organic individual. PNAS USA 1915;1:164-172. Experiments by Hans Spemann and Hilde Mangold in 1924; see http://users.rcn.com/jkimball. ma.ultranet/BiologyPages/Spemann.html.
25. Meinhardt H. Models of biological pattern formation: from elementary steps to organization of embryonic axes. Curr Top Dev Biol 2008;81:1-63.
26. Tsikolia N. What is a role of the morphogen gradients in development? Riv Biol 2003;96:293-315.
27. Tsikolia N. The role and limits of a gradient based explanation of morphogenesis: a theoretical consideration. Int J Dev Biol 2006;50:333-340.
28. Child CM. Patterns and Problems of Development. University of Chicago Press, Chicago, 1941.
29. Fantini B. Embryology, 'chemical geography' of the cell and synthesis between morphology and chemistry (1930-1950). Hist Philos Life Sci 2000;22:353-380.
30. Potter JD. Morphostats: a missing concept in cancer biology. Cancer Epidemiol Biomarkers Prev 2001;10:161-170.
31. Potter JD. Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer 2007;7:464-474.
32. Ku M, Sokol SY, Wu J, Tussie-Luna MI, Roy AL, Hata A. Positive and negative regulation of the transforming growth factor beta/activin target gene goosecoid by the TFII-I family of transcription factors. Mol Cell Biol 2005;25:7144-7157
33. Zhu CC, Yamada G, Blum M. Retinoic acid teratogenicity: the role of goosecoid and BMP-4. Cell Mol Biol (Noisy-le-grand) 1999;45:617-629.
34. Cho KW, Blumberg B, Steinbeisser H, De Robertis EM. Molecular nature of Spemann's organizer: the role of the Xenopus homeobox gene goosecoid. Cell 1991;67:1111-1120.
35. Sonnenschein C, Soto AM. Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. Mol Carcinog 2000;29:205-211.
36. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, Seftor RE, Hendrix MJ. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. PNAS USA 2006;103:3752-3757.
37. Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. PNAS USA 1975;72:3585-3589.
38. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 2002;94:1494-1503.
39. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-245.
40. Walenta S, Doetsch J, Mueller-Klieser W, Kunz-Schughart LA. Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts. J Histochem Cytochem 2000;48:509-622.
41. van Waveren C, Sun Y, Cheung HS, Moraes CT. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix-remodeling genes and invasion. Carcinogenesis 2006;27:409-418.
42. Warburg O. On the origin of cancer cells. Science 1956;123: 309-314.
43. López-Ríos F, Sánchez-Aragó M, García-García E, Ortega AD, Berrendero JR, Pozo-Rodríguez F, López-Encuentra A, Ballestín C, Cuezva JM. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007;67:9013-9017
44. Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B, Steinberg P, Pfeiffer AF, Ristow M. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006;281:977-981.
45. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270.
46. Regoes A, Zourmpanou D, León-Avila G, van der Giezen M, Tovar J, Hehl AB. Protein import, replication, and inheritance of a vestigial mitochondrion. J Biol Chem 2005;280:30557-30563.
47. Nagai S, Mabuchi T, Hirata S, Shoda T, Kasai T, Yokota S, Shitara H, Yonekawa H, Hoshi K. Oocyte mitochondria: strategies to improve embryogenesis. Hum Cell 2004;17:195-201.
48. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 2004;96:1805-1806.
49. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, Zhong H. 'The metabolism of tumours': 70 years later. Novartis Found Symp 2001;240:251-260.
50. Ray S, Ray M. Does excessive adenosine 5′-triphosphate formation in cells lead to malignancy? A hypothesis on cancer. Med Hypotheses 1997;48:473-476.
51. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell 2006;9:419-420.
52. Henschler D. The origin of hormesis: historical background and driving forces. Hum Exp Toxicol 2006;25:347-351.
53. Calabrese EJ, Baldwin LA. Agonist concentration gradients as a generalizable regulatory implementation strategy. Crit Rev Toxicol 2001;31:471-473.
54. van der Woude H, Alink GM, Rietjens IM. The definition of hormesis and its implications for in vitro to in vivo extrapolation and risk assessment. Crit Rev Toxicol 2005;35:603-607.
55. Calabrese EJ. Nitric oxide: biphasic dose responses. Crit Rev Toxicol 2001;31:489-501.
56. 2 action. J Lipid Res 2005;46:736-743.
57. Moreland RB, Kim N, Nehra A, Goldstein I, Traish A. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res 2003;15:362-368.
58. 2 on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochem Pharmacol 2004;67:1259-1267
59. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S, Chayama K. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005;69:1547-1555.
60. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-745.
61. Calabrese EJ. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 2005;35:463-582.
62. Fosslien E. Mitochondrial medicine: molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2000; 30:320-332.
63. Fosslien E. Cancer prevention: Role of preservation of mitochondrial function. Ann Clin Lab Sci 2008;38:181.
64. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-752.
65. Hess AR, Margaryan NV, Seftor EA, Hendrix MJ. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 2007;236:3283-3296.
66. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993;204:356-363.
67. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
68. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Sasaki Y, Hori M, Kawano S. Involvement of cyclooxygenase-2 in proliferation and morphogenesis induced by transforming growth factor alpha in gastric epithelial cells. Prostaglandins Leukot Essent Fatty Acids 1999;61:315-322.
69. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, Pozzi A. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 2007;282:16959-16968.
70. Piguet PF, Grau GE, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 1990;136:103-110.
71. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992;140:539-544.
72. Boca M, Distefano G, Qian F, Bhunia AK, Germino GG, Boletta A. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol 2006;17:637-647
73. Müller M, Morotti A, Ponzetto C. Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 2002;22:1060-1072.
74. Orellana SA, Neff CD, Sweeney WE, Avner ED. Novel Madin Darby canine kidney cell clones exhibit unique phenotypes in response to morphogens. In Vitro Cell Dev Biol Anim 1996;32: 329-339.
75. Ye M, Grant M, Sharma M, Elzinga L, Swan S, Torres VE, Grantham JJ. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol 1992;3:984-994.
76. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004;66:964-973.
77. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57:1460-1471.
78. Fosslien E. Review: Mitochondrial medicin-cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci 2003;33:371-395.
79. VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 2004;3:1605-1613.
80. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, Slingerland J, Arnold RS, Lambeth JD, Cohen C, Hilenski L, Griendling K, Martínez-Diez M, Cuezva JM, Arbiser JL. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117:719-729.
81. Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell RG, Mueller SC, Ojeifo J, Chen WS, Hay N, Pestell RG. Akt1 governs breast cancer progression in vivo. PNAS USA 2007;104:7438-7443.
82. St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer 2004;3:7.
83. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005;7:356-368.
84. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002;62:5551-5558.
85. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2007;96Suppl:R11-15.
86. Brown RE, Tan D, Taylor JS, Miller M, Prichard JW, Kott MM. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuroblastoma, with cell cycle and protein analyte correlates. Ann Clin Lab Sci 2007;37:141-147
87. Paglin S, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, Yahalom J. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005;65:11061-11070.
88. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G, Kozma SC. Disruption of the mouse mTOR gene leads to early post-implantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004;24:9508-9516.
89. Schieke SM, Phillips D, McCoy JP Jr, Aponte AM, Shen RF, Balaban RS, Finke T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006;281:27643-27652.
90. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001;294:1102-1105.
91. Biswas G, Srinivasan S, Anandatheerthavarada HK, Avadhani NG. Dioxin-mediated tumor progression through activation of mitochondria-to-nucleus stress signaling. PNAS USA 2008; 105:186-191.
92. Yu M, Zhou Y, Shi Y, Ning L, Yang Y, Wei X, Shang N, Hao X, Niu R. Reduced mitochondrial DNA copy number is correlated with tumor progression and prognsis in Chinese breast cancer patients. IUBMB Life 2007;59:450-457
93. Woodward ER, Maher ER. Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer 2006;13: 415-425.
94. Rodríguez-Enríquez S, Moreno-Sánchez R. Intermediary metabolism of fast-growth tumor cells. Arch Med Res 1998;29: 1-12.
95. Bayley JP, Devilee P, Taschner PE. The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med Genet 2005;6:39.
96. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006;25:4647-4662.
97. Deschauer M, Gizatullina Z, Schulze A, Pritsch M, Knöppel C, Knape M, Zierz S, Gellerich FN. Molecular and biochemical investigations in fumarase deficiency. Mol Genet Metab 2006; 88:146-152.
98. Favier J, Brière JJ, Strompf L, Amar L, Filali M, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP. Hereditary paraganglioma/ pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 2005;63:171-179.
99. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000;26:268-270.
100. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ, Robinson BG. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 2003;22:1358-1364.
101. Braun S, Riemann K, Kupka S, Leistenschneider P, Sotlar K, Schmid H, Blin N. Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas. Anticancer Res 2005;25:2809-2814.
102. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG. Clinical presentation and penetrance of pheochromocytoma/ paraganglioma syndromes. J Clin Endocrinol Metab 2006;91:827-836.
103. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-951. Erratum: JAMA 2004;292:1686.
104. Pollard PJ, Wortham NC, Tomlinson IP. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med 2003;35:632-639.
105. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-2239.
106. .-, oxidative stress, and genomic instability. Cancer Res 2006;66:7615-7620.
107. Selak MA, Durán RV, Gottlieb E. Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim Biophys Acta 2006;1757:567-572.
108. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85.
109. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002;277:23111-23115.
110. 2 production in human prostate cancer cells. Anticancer Res 2002;22:1491-1496.
111. Shidaifat F, Canatan H, Kulp SK, Sugimoto Y, Chang WY, Zhang Y, Brueggemeier RW, Somers WJ, Lin YC. Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-beta. Cancer Lett 1996;107:37-44.
112. Jiang J, Sugimoto Y, Liu S, Chang HL, Park KY, Kulp SK, Lin YC. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res 2004;24:91-100.
113. Senthilnathan P, Padmavathi R, Magesh V, Sakthisekaran D. Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer. Life Sci 2006;78: 1010-1014.
114. Pocernich CB, Butterfield DA. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res 2003;5:515-520.
115. Ttettet L, Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of α-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 2000;20:8972-8979.
116. Yarian CS, Sohal RS. In the aging housefly aconitase is the only citric acid cycle enzyme to decline significantly. J Bioenerg Biomembr 2005;37:91-96.
117. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59:10-16.
118. Mason KE, Stofan DA. Endotoxin challenge reduces aconitase activity in myocardial tissue. Arch Biochem Biophys 2008;469: 151-156.
119. Mamelak AJ, Kowalski J, Murphy K, Yadava N, Zahurak M, Kouba DJ, Howell BG, Tzu J, Cummins DL, Liégeois NJ, Berg K, Sauder DN. Downregulation of NDUFA1 and other oxidative phosphorylation-related genes is a consistent feature of basal cell carcinoma. Exp Dermatol 2005;14:336-348.
120. Au HC, Seo BB, Matsuno-Yagi A, Yagi T, Scheffler IE. The NDUFA1 gene product (MWFE protein) is essential for activity of complex I in mammalian mitochondria. PNAS USA 1999;96:4354-4359.
121. Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE, Hirst J. GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH57 ubiquinone oxidoreductase (complex I). J Biol Chem 2001;276:38345-38348.
122. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, Lufei C, Zeng Q, Cao X. GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 2004;24:8447-8456.
123. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell 1999;98:295-303.
124. Papa S. The NDUFS4 nuclear gene of complex I of mitochondria and the cAMP cascade. Biochim Biophys Acta 2002;1555:147-153.
125. 2 on hepatic mitochondrial function of the preserved rat liver. Tohoku J Exp Med 1986;150:373-379.
126. Sandal T, Valyi-Nagy K, Spencer VA, Folberg R, Bissell MJ, Maniotis AJ. Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme. Am J Pathol 2007;170: 1739-1749.
127. Cochemé HM, Murphy MP. Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem 2008;283:1786-1798.
128. Monge P, Wesseling C, Guardado J, Lundberg I, Ahlbom A, Cantor KP, Weiderpass E, Partanen T. Parental occupational exposure to pesticides and the risk of childhood leukemia in Costa Rica. Scand J Work Environ Health 2007;33:293-303.
129. Lee WJ, Colt JS, Heineman EF, McComb R, Weisenburger DD, Lijinsky W, Ward MH. Agricultural pesticide use and risk of glioma in Nebraska, United States. Occup Environ Med 2005;62:786-792.
130. 10 deficiency. FASEB J 2008;22: 1874-1885.
131. 10. A review of animal and human publications. Biofactors 2003;18:101-111.
132. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, Mootha VK. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 2008; 26:343-351.
133. Choksi KB, Papaconstantinou J. Age-related alterations in oxidatively damaged proteins of mouse heart mitochondrial electron transport chain complexes. Free Radic Biol Med 2008; 44:1795-1805.
134. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev 2007;39:443-455.
135. Salvi M, Brunati AM, Clari G, Toninello A. Interaction of genistein with the mitochondrial electron transport chain results in opening of the membrane transition pore. Biochim Biophys Acta 2002;1556:187-196.
136. Tuquet C, Dupont J, Mesneau A, Roussaux J. Effects of tamoxifen on the electron transport chain of isolated fat liver mitochondria. Cell Biol Toxicol 2000;16:207-219.
137. Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, Grammatico P. Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat 2008; 110:439-452.
138. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006;66:6087-6096.
139. Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 2001;86: 4920-4925.
140. Stankov K, Biondi A, D'Aurelio M, Gasparre G, Falasca A, Romeo G, Lenaz G. Mitochondrial activities of a cell line derived from thyroid Hürthle cell tumors. Thyroid 2006;16:325-331.
141. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Béroud C, Demont J, Bouvier R, Schägger H, Godinot C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002;23: 759-768.
142. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science 2006;312:1650-1653.
143. Fosslien E. Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001;31: 25-67.
144. 0-ATP synthase and inhibits mitochondrial function in sperm. Biochem Biophys Res Commun 2008;366:66-72.
145. Sass JB, Colangelo A. European Union bans atrazine, while the United States negotiates continued use. Int J Occup Environ Health 2006;12:260-267.
146. Levy SE, Chen YS, Graham BH, Wallace DC. Expression and sequence analysis of the mouse adenine nucleotide translocase 1 and 2 genes. Gene 2000;254:57-66.
147. Li K, Hodge JA, Wallace DC. OXBOX, a positive transcriptional element of the heart-skeletal muscle ADP/ATP translocator gene. J Biol Chem 1990;265:20585-20588.
148. 1-ATP synthase beta subunit gene. OXBOX/REBOX in the ATPsyn beta promoter J Biol Chem 1994;269:9330-9334.
149. Chung AB, Stepien G, Haraguchi Y, Li K, Wallace DC. Transcriptional control of nuclear genes for the mitochondtial muscle ADP/ATP translocator and the ATP synthase beta subunit. Multiple factors interact with the OXBOX/REBOX promoter sequences. J Biol Chem 1992;267:21154-21161.
150. Law AK, Gupta D, Levy S, Wallace DC, McKeon RJ, Buck CR. TGF-beta1 induction of the adenine nucleotide translocator 1 in astrocytes occurs through Smads and Sp1 transcription factors. BMC Neurosci 2004;5:1.
151. Battini R, Ferrari S, Kaczmarek L, Calabretta B, Chen ST, Baserga R. Molecular cloning of a cDNA for a human ADP/ ATP carrier which is growth-regulated. J Biol Chem 1987;262: 4355-4359.
152. Li R, Luciakova K, Zaid A, Betina S, Fridell E, Nelson BD. Thyroid hormone activates transcription from the promoter regions of some human nuclear-encoded genes of the oxidative phosphorylation system. Mol Cell Endocrinol 1997;128:69-75.
153. Barath P, Poliakova D, Luciakova K, Nelson BD. Identification of NF1 as a silencer protein of the human adenine nucleotide translocase-2 gene. Eur J Biochem 2004;271:1781-1788.
154. Giraud S, Bonod-Bidaud C, Wesolowski-Louvel M, Stepien G. Expression of human ANT2 gene in highly proliferative cells: GRBOX, a new transcriptional element, is involved in the regulation of glycolytic ATP import into mitochondria. J Mol Biol 1998;281:409-418.
155. Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthièry Y, Stepien G. ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr 2005;37:307-316.
156. Bonod-Bidaud C, Chevrollier A, Bourasseau I, Lachaux A, Mousson de Camaret B, Stepien G. Induction of ANT2 gene expression in liver of patients with mitochondrial DNA depletion. Mitochondrion 2001;1:217-224.
157. Li R, Hodny Z, Luciakova K, Barath P, Nelson BD. Sp1 activates and inhibits transcription from separate elements in the proximal promoter of the human adenine nucleotide translocase 2 (ANT2) gene. J Biol Chem 1996;271:18925-18930.
158. Zaid A, Li R, Luciakova K, Barath P, Nery S, Nelson BD. On the role of the general transctiption factor Sp1 in the activation and epression of diverse mammalian oxidative phosphorylation genes. J Bioenerg Biomembr 1999;31:129-135.
159. Zaid A, Hodny Z, Li R, Nelson BD. Sp1 acts as a repressor of the human adenine nucleotide translocase-2 (ANT2) promoter. Eur J Biochem 2001;268:5497-5503.
160. Wimmer EA, Jäckle H, Pfeifle C, Cohen SM. A Drosophila homologue of human Sp1 is a head-specific segmentation gene. Nature 1993;366:690-694.
161. Yang Z, Cheng W, Hong L, Chen W, Wang Y, Lin S, Han J, Zhou H, Gu J. Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells. Mol Biol Cell 2007;18:4681-4689.
162. Volcik KA, Shaw GM, Zhu H, Lammer EJ, Finnell RH. Risk factors for neural tube defects: associations between uncoupling protein 2 polymorphisms and spina bifida. Birth Defects Res A Clin Mol Teratol 2003;67:158-161.
163. 2 on energy metabolism in isolated rat liver mitochondria. Vopr Med Khim 1982;28:110-114.
164. Chevillotte E, Rieusset J, Roques M, Desage M, Vidal H. The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta. J Biol Chem 2001;276:10853-10860.
165. Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM. Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci 2007;12:3333-3342.
166. Rundhaug JE, Mikulec C, Pavone A, Fischer SM. A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis. Mol Carcinog 2007;46:692-698.
167. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
168. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
169. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007;58:239-252.
170. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 2005;14:2840-2847.
171. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res 2007;67:3976-3985.
172. 2 dependent cell survival through the PI3 kinase/ AKT path way. Prostaglandins Other Lipid Mediat 2007;83:112-120.
173. 2 receptors and clinicopathologic features in human prostate cancer tissue. Urology 2006;68:1360-1365.
174. 2 level via cPLA2-COX-2-mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats. Prostaglandins Leukot Essent Fatty Acids. 2006;74:309-315.
175. Chen KH, Hsu WM, Chiang CC, Li YS. Transforming growth factor-beta2 inhibition of corneal endothelial proliferation mediated by prostaglandin. Curr Eye Res 2003;26:363-370.
176. Ohyama T. Effects of phthalate esters on the latent ATPase and swelling of mitochondria. J Biochem 1977;82:9-15.
177. Grolier P, Elcombe CR. In vitro inhibition of carnitine acyltransferase activity in mitochondria from rat and mouse liver by a diethylhexylphthalate metabolite. Biochem Pharmacol 1993;45:827-832.
178. Melnick RL, Schiller CM. Mitochondrial toxicity of phthalate esters. Environ Health Perspect 1982;45:51-56.
179. Ohyama T. Effects of phthalate esters on the respiration of rat liver mitochondria. J Biochem 1976;79:153-158.
180. Melnick RL, Schiller CM. Effect of phthalate esters on energy coupling and succinate oxidation in rat liver mitochondria. Toxicology 1985;34:13-27
181. Winberg LD, Badr MZ. Mechanism of phthalate-induced inhibition of hepatic mitochondrial beta-oxidation. Toxicol Lett 1995;76:63-69.
182. Bell FP. Effects of phthalate esters on lipid metabolism in various tissues, cells and organelles in mammals. Environ Health Perspect 1982;45:41-50.
183. Kora S, Sado M, Terada H. Effect of the plasticizer di-(2-ethylhexyl) phthalate on oxidative phosphorylation in rat liver mitochondria: modification of the function of the adenine nucleotide translocator. J Pharmacobiodyn 1988;11:773-778.
184. Wittassek M, Angerer J. Phthalates: metabolism and exposure. Int J Androl 2008;31:131-138.
185. Sathyanarayana S, Karr CJ, Lozano P, Brown E, Calafat AM, Liu F, Swan SH. Baby care products: possible sources of infant phthalate exposure. Pediatrics 2008;121:e260-e268.
186. 1-ATP synthase and ubiquinone. Toxicol Appl Pharmacol 2006; 217:363-374.
187. Steenland K, Bertazzi P, Baccarelli A, Kogevinas M. Dioxin revisited: developments since the 1997 IARC classification of dioxin as a human carcinogen. Environ Health Perspect 2004; 112:1265-1268.
188. Hardell L. Pesticides, soft-tissue sarcoma and non-Hodgkin lymphoma-historical aspects on the precautionary principle in cancer prevention. Acta Oncol 2008;47:347-354.
189. Phillips KP, Tanphaichitr N. Human exposure to endocrine disruptors and semen quality. J Toxicol Environ Health B Crit Rev 2008;11:188-220.
190. 1 during hepatocarcinogenesis. Science 1982;215:73-75.
191. Sajan MP, Satav JG, Bhattacharya RK. Activity of some respiratory enzymes and cytochrome contents in rat hepatic mitochondria following anatoxin B1 administration. Toxicol Lett 1995;80:55-60. Erratum: Toxicol Lett 1996;84:125.
192. Su H, Zhao J, Xiong Y, Xu T, Zhou F, Yuan Y, Zhang Y, Zhuang SM. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res 2008;641:27-35.
193. Tsay HJ, Wang YH, Chen WL, Huang MY, Chen YH. Treatment with sodium benzoate leads to malformation of zebrafish larvae. Neurotoxicol Teratol 2007;29:562-569.
194. Norman C, Howell KA, Millar AH, Whelan JM, Day DA. Salicylic acid is an uncoupler and inhibitor of mitochondrial electron transport. Plant Physiol 2004;134:492-501.
195. Yeh TC, Chiang PC, Li TK, Hsu JL, Lin CJ, Wang SW, Peng CY, Guh JH. Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochem Pharmacol 2007;73: 782-792.
196. Renner R, Innis SM, Clandinin MT. Effects of high and low erucicacid rapeseed oil on energy metabolism and mitochondrial functions of the chick. J Nutr 1979;109:376-387.
197. Chen J, Siddiqui A. Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidant stress. J Virol 2007;81:6757-6760.
198. Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, Godinot C. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005;26:531-539.